Schedule 13G ownership disclosure
VERTEX PHARMACEUTICALS INC COM
Security class unavailable · CUSIP: 92532F100
Event date: 2016-12-31
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 21,860,325
- Percent of class
- 8.8000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000080255-17-001238
- Form type
- SC 13G
- Filer
- PRICE T ROWE ASSOCIATES INC /MD/
- CIK
- CIK 80255
- Filed
- Feb 07, 2017
- Reporting period
- Dec 31, 2016
- Description
- Schedule 13G beneficial ownership